FDA Approves DATROWAY® for Advanced HR+/HER2- Breast Cancer
Trop-2-directed antibody-drug conjugateA new breast cancer treatment option
The United States Food and Drug Administration (FDA) approved DATROWAY® (datopotamab deruxtecan-dlnk) on January 17, 2025, for adults with hormone receptor-positive (HR+), HER2-negative breast cancer that is unresectable or metastatic and has already been treated with both endocrine therapy and chemotherapy.
What is DATROWAY?
DATROWAY is a Trop-2-directed antibody-drug conjugate that delivers a chemotherapy payload directly to cancer cells. It was developed by Daiichi Sankyo, Inc.
Administration
DATROWAY is administered via IV infusion once every 3 weeks.
Clinical Trial Snapshot
- Trial Name: TROPION-Breast01
- Patients: 732 (across 20 countries; 59 from the U.S.)
- Design: Compared DATROWAY vs. chemotherapy
- Key Results:
- Progression-Free Survival (PFS):
- DATROWAY: 6.9 months
- Chemotherapy: 4.9 months
- Also showed improved response rates and duration of response.
Potential Side Effects
DATROWAY may cause:
- Severe lung problems, including life-threatening or fatal interstitial lung disease (ILD)
- Mouth sores, eye irritation, keratitis
- Risk to unborn babies
Most common side effects include:
- Mouth ulcers, nausea, fatigue
- Low white/red blood cell counts, hair loss
- Constipation, dry eyes, liver enzyme elevation
Summary
DATROWAY offers a new treatment option for patients with difficult-to-treat HR+/HER2- breast cancer, showing better cancer control than standard chemo — but it carries significant risks that must be carefully managed.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Approves Thoracic Stent Graft System
FDA Approves RelayPro Thoracic Stent Graft System for Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers Treatment The United States Food and Drug Administration (FDA) on March 7, 2023 approved the RelayPro Thoracic Stent Graft System, a new medical...
Abbott Safety Alert for Freestyle Libre Systems
Misuse may cause battery overheating and incorrect readings The FDA has issued a safety notification regarding the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems. The notification warns users of the potential for...
Camber Recalls Atovaquone Oral Suspension USP
Camber Recalls Atovaquone Oral Suspension USP for Potential Contamination Camber Pharmaceuticals Inc. recently issued a voluntary nationwide recall of Atovaquone Oral Suspension USP due to potential contamination. The recall was announced by the U.S. Food and Drug...